Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States.
Wongvibulsin S, Sutaria N, Williams KA, Huang AH, Choi J, Roh YS, Hong M, Kelley D, Pahalyants V, Murphy W, Alphonse MP, Bakhshi P, Walia A, Semenov YR, Kwatra SG. Wongvibulsin S, et al. Among authors: pahalyants v. J Invest Dermatol. 2021 Oct;141(10):2530-2533.e1. doi: 10.1016/j.jid.2021.02.756. Epub 2021 Apr 3. J Invest Dermatol. 2021. PMID: 33823182 Free PMC article. No abstract available.
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Klebanov N, Pahalyants V, Murphy WS, Theodosakis N, Zubiri L, Klevens RM, Kwatra SG, Lilly E, Reynolds KL, Semenov YR. Klebanov N, et al. Among authors: pahalyants v. Oncologist. 2021 May;26(5):e898-e901. doi: 10.1002/onco.13768. Epub 2021 Apr 17. Oncologist. 2021. PMID: 33783099 Free PMC article.
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Kalinich M, et al. Among authors: pahalyants v. J Immunother Cancer. 2021 Mar;9(3):e001935. doi: 10.1136/jitc-2020-001935. J Immunother Cancer. 2021. PMID: 33789879 Free PMC article.
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR. Wongvibulsin S, et al. Among authors: pahalyants v. J Am Acad Dermatol. 2022 Mar;86(3):563-572. doi: 10.1016/j.jaad.2021.03.094. Epub 2021 Apr 2. J Am Acad Dermatol. 2022. PMID: 33819538 Free PMC article.
Characterization of the active Medicare dermatology workforce.
Murphy W, Pahalyants V, Gunasekera N, Shi CR, Nambudiri VE. Murphy W, et al. Among authors: pahalyants v. J Am Acad Dermatol. 2022 May;86(5):1140-1142. doi: 10.1016/j.jaad.2021.03.123. Epub 2021 Apr 18. J Am Acad Dermatol. 2022. PMID: 33878408 No abstract available.
Latent class analysis identification of prurigo nodularis comorbidity phenotypes.
Wongvibulsin S, Parthasarathy V, Pahalyants V, Murphy W, Sutaria N, Roh YS, Bordeaux ZA, Deng J, Taylor MT, Semenov YR, Kwatra SG. Wongvibulsin S, et al. Among authors: pahalyants v. Br J Dermatol. 2022 May;186(5):903-905. doi: 10.1111/bjd.20957. Epub 2022 Mar 25. Br J Dermatol. 2022. PMID: 34927720 No abstract available.
32 results